What is GEN inCode?
GEN inCode is a pioneering company specializing in genomic testing for the prevention, diagnosis, and treatment of cardiovascular disease. Their innovative approach integrates both monogenic and polygenic risk assessments to deliver comprehensive risk evaluations. These evaluations empower physicians with critical data to make more informed clinical decisions. The company's product portfolio includes CARDIO inCode-Score and LIPID inCode, both designed to optimize patient treatment pathways. By focusing on advanced patient risk assessment, GENinCode is actively working to combat cardiovascular disease, a leading global health challenge.
How much funding has GEN inCode raised?
GEN inCode has raised a total of $4.5M across 1 funding round:
Unspecified
$4.5M
Unspecified (2020): $4.5M with participation from Maven Capital Partners UK LLP
Key Investors in GEN inCode
Maven Capital Partners UK LLP
Maven Capital Partners UK LLP is a venture capital firm that invests in companies across various sectors. Their involvement suggests a strategic interest in GEN inCode's innovative approach to genomic testing and cardiovascular health.
What's next for GEN inCode?
With the recent infusion of enterprise-level capital, GEN inCode is poised for accelerated growth and expansion. The company is expected to leverage this strategic backing to further develop its genomic testing technologies, enhance its product offerings, and broaden its market reach. This investment signals a strong belief in GEN inCode's potential to significantly impact the healthcare landscape by providing precise tools for cardiovascular risk management. Future initiatives will likely focus on clinical validation, strategic partnerships, and scaling operations to meet the increasing demand for personalized genetic diagnostics in cardiology.
See full GEN inCode company page
